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ABSTRACT
Most actions of glucocorticoids (GCs) are mediated by the glucocorticoid receptor (GR). The
interindividual response to GCs varies considerably, as demonstrated by a variable suppressive
response to 0.25-mg dexamethasone (DEX). Several polymorphisms in the gene coding for the GR
have been described. It is unclear to what extent the observed response variability is due to GR
polymorphisms or to other factors. However, at least three polymorphisms seem to be associated with
altered GC sensitivity and changes in body composition and metabolic parameters. The N363S
polymorphism has been associated with increased sensitivity to GCs, increased insulin response to
DEX, a tendency towards lower bone mineral density, and increased body mass index (BMI).
However, other reports found no associations with BMI. Another polymorphism, previously de-
scribed as a BclI restriction fragment length polymorphism, recently was identified as a C 3 G
nucleotide change. The G allele also was associated with increased sensitivity to GCs. In middle-aged
subjects, the G allele of this BclI polymorphism was associated with increased abdominal obesity,
while at older age, a lower BMI was found, accompanied by a tendency towards lower lean body
mass. A third polymorphism consists of two linked, single-nucleotide mutations in codons 22 and 23,
of which the second mutation results in an amino acid change from arginine (R) to lysine (K). In
contrast to the other polymorphisms, this ER22/23EK polymorphism was associated with a relative
resistance to GCs. In line with this, ER22/23EK carriers had lower total cholesterol and low-density
lipoprotein cholesterol levels as well as lower fasting insulin concentrations and a better insulin
sensitivity. C-reactive protein levels were lower in ER22/23EK carriers, as was found in a different
population of elderly males. In accordance with this healthy metabolic profile, we found in this
population a significantly better survival in ER22/23EK carriers after a 4-year follow-up. GCs also
affect the brain. Although a certain level of cortisol is essential for proper brain functioning, excessive
GC levels have been shown to negatively affect brain morphology and functions. At older age, we
found that the risk of dementia and white matter lesions was lower in ER22/23EK carriers. GCs are
also important in the regulation of body fat distribution. At young age, we observed sex-specific
differences in body composition. Male ER22/23EK carriers were taller, had more muscle mass, and
were stronger than noncarriers. In young females, ER22/23EK carriers had tendencies towards
smaller waist and hip circumferences and lower body weight. Another polymorphism (TthIIII) was
not associated with altered GC sensitivity. In conclusion, these polymorphisms in the GR gene may
contribute considerably to the observed variability in GC sensitivity. As a result, they are associated
with several differences in body composition and metabolic factors.
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I. Introduction
Glucocorticoid (GC) secretion is regulated by the hypothalamus, which
receives stimuli from the central nervous system (CNS) (Chrousos and Gold,
1992). This results in a diurnal profile of cortisol secretion, with high levels in the
morning and low concentrations in the afternoon and evening, with a small peak
after lunch. In obese individuals, cortisol secretion is elevated and its peripheral
turnover rate is higher, which results in normal, or even lower, serum cortisol
concentrations (Murphy, 1968; Streeten et al., 1969; Cheek et al., 1981).
Dysregulation of the hypothalamo-pituitary-adrenal (HPA) axis was found to be
more pronounced in central obesity than in peripheral or gluteofemoral obesity
(Marin et al., 1992; Pasquali et al., 1993; Rosmond et al., 1998).
The regulation of cortisol metabolism in humans is not only centrally
determined. Two key enzymes in cortisol metabolism have been identified that
influence the effects of cortisol at the peripheral level: 11beta-hydroxysteroid
dehydrogenase (11-HSD) I and 11-HSD II. The latter enzyme inactivates
cortisol by conversion into cortisone, particularly in the kidney but also in other
aldosterone-selective target tissues. The other enzyme, 11-HSD I, is present
predominantly in adipose tissue, liver, lung, vascular system, ovary, and CNS
(Monder and White, 1993; Stewart and Krozowski, 1999). The function of
11-HSD I is to convert cortisone into the active form, cortisol. Interestingly, in
obese humans, this enzyme has been shown to have tissue-specific actions.
11-HSD I activity is lower in the liver, while increased activity in vitro is
observed in the subcutaneous adipose tissue of obese men. This results in higher
local cortisol levels in adipose tissue, which is suggested to be an important
factor in the mechanism leading to harmful metabolic consequences of obesity.
It is known that GC sensitivity, measured by a dexamethasone (DEX)
suppression test, varies greatly between individuals (Huizenga et al., 1998b).
However, within individuals, GC sensitivity is rather stable. This suggests that,
in humans, a setpoint for DEX sensitivity with respect to the feedback action
exists, which might be genetically determined. An important factor in the cascade
of GC action, also at the pituitary level, is binding to the GC receptor (GR).
The GR belongs to the superfamily of nuclear receptors that are present in
the cytoplasm and act as transcription factors to regulate gene expression.
Following cortisol binding, a conformational change occurs that leads to disso-
ciation of the receptor from a large complex of proteins, of which heat shock
protein (HSP) 90 is the most important (Pratt and Toft, 1997; Toft, 1998). This
activated, ligand-bound receptor translocates to the nucleus, where it can act in
several ways (Schaaf and Cidlowski, 2003). The GR can initiate transcription
through binding to GC-responsive elements of the target gene. The GR also can
affect gene transcription through direct protein-protein interaction and can
activate, as well as repress, target gene expression (Diamond et al., 1990;
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Yang-Yen et al., 1990; Yudt and Cidlowski, 2002). In mice in which a mutation
was induced that impaired dimerization and DNA binding, these processes have
been shown to be not critical for survival (Reichardt et al., 1998).
Previously, some rare mutations of the GR gene were described that led to
clinical signs and symptoms of generalized cortisol resistance (Lamberts et al.,
1992). Due to these receptor defects, cortisol has impaired actions through the
GR. As a consequence, the central negative feedback of GCs is diminished, GC
production by the adrenal is elevated, and cortisol binds with high affinity to the
mineralocorticoid receptor (MR). Symptomatology in patients with cortisol
resistance is the consequence of a compensatory hyperactivity of the HPA axis,
which results in overproduction of mineralocorticoids, which, in turn, leads to
hypertension, hypokalemic alkalosis, fatigue, and in females — due to higher
adrenal production of androgens — hyperandrogenism. In normal conditions,
organs that have an important mineralocorticoid function are protected from high
cortisol levels by the enzyme 11-HSD II, which rapidly inactivates cortisol into
cortisone. In the situation of cortisol resistance, cortisol levels are too high for the
inactivational capacity of this enzyme. The number of patients diagnosed with
cortisol resistance syndrome is low (i.e.,  nine) (Brufsky et al., 1990; Hurley et
al., 1991; Karl et al., 1993,1996a; Malchoff et al., 1993; Ruiz et al., 2001;
Mendonca et al., 2002; Vottero et al., 2002). Two mutations found in vitro could
have been pre-existing acquired mutations in vivo, leading to Nelson syndrome
and lupus nephritis (Karl et al., 1996b; Jiang et al., 2001). Most patients carried
a mutation or defect in the ligand-binding domain; only one patient had a
mutation in the DNA-binding domain (Lamberts, 2001). A possible explanation
for the low number of patients is that a severe form of cortisol resistance is not
compatible with life.
Hypersensitivity to endogenous cortisol has been described as well. Iida and
colleagues (1990) reported a patient with symptoms of Cushing’s syndrome,
despite hypocortisolemia. Newfield and coworkers (2000) described a second
patient with serious symptoms of Cushing’s syndrome at peripubertal age but
having normal cortisol levels. The lymphocytes of this second patient contained
an increased number of GR per cell, with normal binding affinity. The molecular
etiology of hyperreactivity to cortisol has not been clarified fully but two
single-nucleotide polymorphisms of the GR gene seem to play an important role
in determining hypersensitivity. Figure 1 shows a schematic overview of the GR
gene, with locations of previously described mutations causing cortisol resistance
and of polymorphisms shown to be associated with altered GC sensitivity. In
contrast to the infrequent mutations, most polymorphisms are located in the
N-terminal transactivation domain (Bray and Cotton, 2003). This review deals
with these GR gene polymorphisms, which were not only associated with
differences in GC sensitivity but also related to differences in body composition
and metabolic parameters.
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II. The N363S Polymorphism of the GR Gene
A polymorphism was identified in codon 363 of exon 2 of the GR gene.
Table I shows an overview of the associations with body mass index (BMI) and
metabolic parameters found with this polymorphism.
This AAT 3 AGT nucleotide change results in an asparagine 3 serine
amino acid change. It appeared in a group of 216 normal Dutch elderly
individuals known to be associated with a higher sensitivity to GCs in vivo
(Koper et al., 1997; Huizenga et al., 1998a). This was shown by lower cortisol
levels after administration of 0.25-mg DEX (Figure 2A) as well as a significantly
greater decrease in cortisol levels (Figure 2B). Moreover, in this population,
N363S carriers had an increased insulin response to exogenous DEX, which is
likely to be related directly to their increased GC sensitivity. N363S carriers had
a higher BMI and a tendency towards decreased bone mineral density in
trabecular bone (Huizenga et al., 1998a; Lin et al., 1999). Lin and colleagues
(1999) confirmed the association with BMI and even demonstrated an allele-
dosage effect on BMI (i.e., homozygous S-allele carriers had a higher BMI than
heterozygous S-allele carriers). However, some controversy arose concerning the
role of this polymorphism, as reviewed by Rosmond (2002). Dobson et al. (2001)
found an increased waist-to-hip ratio in male N363S carriers but no associations
with BMI, serum lipid levels, and glucose tolerance status in a Caucasian
population. In three other reports, no association was observed between the
N363S polymorphism and BMI (Halsall et al., 2000; Echwald et al., 2001;
Rosmond et al., 2001). However, in a severely obese Italian population, the
N363S variant was associated with increased BMI. Heterozygous carriers of both
the N363S and the BclI polymorphism had higher cholesterol levels (Di Blasio
et al., 2003). In a recent report by Lin and coworkers (2003b), the N363S variant
was associated with coronary artery disease, independent of weight. 363S allele
FIG. 1. Schematic overview of the GR gene, showing polymorphisms (white arrows), which
have been shown to alter glucocorticoid (GC) sensitivity and are associated with differences in body
composition, as well as mutations (black arrows) leading to the syndrome of cortisol resistance.
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frequency was particularly high in patients with angina pectoris. In this popula-
tion of Anglo-Celtic descent, several atherosclerosis risk factors were associated
with the N363S variant: increased cholesterol and triglyceride concentrations and
a higher total cholesterol/high-density lipoprotein (HDL) cholesterol ratio. The
same authors showed an association between the N363S polymorphism and
TABLE I
Data from Six Studies That Investigated the Association Between the N363S Polymorphism of the
Glucocorticoid Receptor (GR) Gene and Body Mass Index
Reference Population
Associations with the N363S
polymorphism
Huizenga et al.,
1998a
216 Dutch men and women Increased GC sensitivity, increased
insulin response to DEX,
increased BMI
Lin et al., 1999 195 normotensive controls and
124 hypertensive subjects
Increased BMI, allele-dosage effect
Halsall et al.,
2000
491 subjects No association with BMI
Dobson et al.,
2001
135 men and 240 women Increased WHR in men
Rosmond et al.,
2001b
284 Swedish men No association with BMI, no
association with sensitivity
to GCs
Echwald et al.,
2001
741 obese Danish men and 854
non-obese controls
No association with BMI, WHR, or
weight gain
Lin et al.,
2003b
437 Anglo-Celtic CAD patients
and 302 controls
Association with CAD, elevated
cholesterol, triglycerides, total
cholesterol/HDL ratio
Lin et al.,
2003a
951 Anglo-Celtic/Northern
European subjects: 152
obese, 356 type 2 diabetes,
141 hypertensive, 302
controls
Association with obesity and
overweight in several patient
settings but no association with
hypertension or type 2 diabetes
Di Blasio et al.,
2003
185 obese women, 94 obese men Increased BMI, interaction with the
BclI polymorphism: higher
cholesterol levels
[Abbreviations: BMI, body mass index; CAD, coronary artery disease; DEX, dexamethasone;
GC, glucocorticoid; HDL, high-density lipoprotein-cholesterol; WHR, waist-to-hip ratio.]
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obesity as well as overweight in several groups of patients (Lin et al., 2003a).
However, no association was found with hypertension or type 2 diabetes.
Interestingly, in a Japanese as well as in a Chinese population, the N363S variant
did not occur (Ikeda et al., 2001; Lei et al., 2003).
FIG. 2. Cortisol levels (nmol/l) after dexamethasone (DEX) suppression tests (graphs on the
left: A, C, E) and absolute change in cortisol (nmol/l) after DEX (graphs on the right: B, D, F).
Results from a 0.25-mg DEX suppression test are shown for N363S and BclI carriers. Data
concerning a 1-mg test are shown for ER22/23EK carriers. (A & B) Noncarriers (white bars) were
compared to N363S carriers (striped bars). Lower post-DEX cortisol and greater decrease in N363S
carriers suggest a hypersensitivity to GCs. (C & D) Heterozygous and homozygous BclI G-allele
carriers (black bars), also lower post-DEX cortisol and greater decrease in BclI G-allele carriers,
suggesting that BclI G-allele carriers are hypersensitive to GCs. (E & F) ER22/23EK carriers
(vertically striped bars), who had higher cortisol levels after 1-mg DEX and a smaller decrease in
cortisol, which suggests that the ER22/23EK variant is associated with a relative resistance to GCs.
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Figure 3 shows the DEX concentrations necessary to achieve 50% of the
maximal inhibition (IC50) in mitogen-induced, in vitro cell proliferation assays
in noncarriers and N363S carriers (Huizenga et al., 1998a). A trend was observed
towards a lower IC50 in carriers of the N363S polymorphism, which supports the
observation of increased sensitivity to GCs in vivo. We have to take in to account
that in the group of noncarriers (left dots in Figure 3), carriers of the very
frequent BclI polymorphism are present. This polymorphism has been associated
with increased GC sensitivity. As a consequence, differences in IC50 in Figure
3 between “real noncarriers” (i.e., noncarriers of both N363S and BclI) and
N363S carriers probably are underestimated. This underestimation might apply
to other studies comparing noncarriers and N363S in body composition and
metabolic parameters.
The exact mechanism underlying increased sensitivity to GCs is unknown.
In in vitro expression experiments using a mouse mammary tumor virus-driven/
luciferase expression (MMTV-LUC) system, no differences were observed
FIG. 3. Concentrations of DEX necessary to achieve 50% of the maximal inhibition (IC50) in
mitogen-induced peripheral mononuclear cell proliferation assays in noncarriers and carriers of the
N363S polymorphism. A trend was observed towards a lower mean IC50 in N363S carriers,
compared to noncarriers. [Adapted with permission from Huizenga NA, Koper JW, De Lange P, Pols
HA, Stolk RP, Burger H, Grobbee DE, Brinkmann AO, De Jong FH, Lamberts SW 1998 A
polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity
to glucocorticoids in vivo. J Clin Endocrinol Metab 83:144–151. Copyright The Endocrine Society.]
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between the N363S variant GR and wild-type GR in efficacy to activate
transcription (de Lange et al., 1997). However, Feng and colleagues (2000)
suggested that the N363S variant modulated the phosphorylation state of the GR
and might alter interactions with other transcription factors. No evidence for this
hypothesis has been found. However, in two reports, GR hyperactivity was
induced by in vitro-created mutants, resulting in increased transcriptional activity
and a diminished capacity to repress activator protein-1 (AP-1) induction (Heck
et al., 1994; Guido et al., 1996).
III. The BclI Polymorphism of the GR Gene
Murray et al. (1987) reported an intronic restriction fragment length poly-
morphism (RFLP) of the GR gene, which was described as consisting of a short
fragment of 2.3 kb and a large fragment of 4.5 kb. Since then, several association
studies have been performed to investigate the role of this variant in obesity,
using Murray’s terminology and technique. Recently, we identified the exact
nucleotide alteration: a C3 G mutation, 646 nucleotides downstream from exon
2, which results in fragments of 2.2 kb and 3.9 kb (van Rossum et al., 2003b).
The C allele is the most-frequently occuring and thus can be considered the
wild-type allele (Table II). Table III displays an overview of reports of the BclI
polymorphism and its associations with body composition and metabolic param-
eters.
The first association study of the BclI polymorphism, decribed by Weaver
and coworkers (1992), showed no differences in BclI polymorphism frequency
between an obese and a normal-weight population. However, within the obese
group, homozygous G-allele (4.5 kb) carriers had higher insulin levels and were
TABLE II
Fragments Length of the BclI and the TthIIII Restriction Fragment Polymorphism and Their
Corresponding Nucleotide Changes as Well as Allelic Frequencies
RFLP
Length restriction
fragmenta Nucleotide change
Allele
frequencyb
BclI 2.3 kb C 65%
4.5 kb G 35%
TthIIII 3.4 kb C 62%
3.8 kb T 38%
aFragment length as described in literature. After identification of the exact nucleotide change,
we found that the fragments of the BclI polymorphism were 2.2 kb and 3.9 kb, respectively. bAllele
frequency as observed in a subset of subjects from the Rotterdam study, a population-based study in
the elderly. RFLP, restriction fragment length polymorphism.
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TABLE III
Data from Studies That Involved the BclI Polymorphism of the GR Gene and Investigated
Whether Differences Existed Between CC Carriers, CG Carriers, and GG Carriers in Body
Composition, Blood Pressure, and Metabolic Parameters
Reference Population
Associations with the G allele of the BclI
polymorphism
Weaver et al.,
1992
56 Obese and 43 non-obese
premenopausal women
Hyperinsulinemia in obese GG carriers but not
in non-obese GG carriers, no association
of the G allele with obesity
Watt et al., 1992 864 Adults (aged 16–24
years) and their parents
Homozygosity for the G allele was more
frequent in the group with personal and
parental hypertension
Clement et al.,
1996
80 Obese families Tendency towards linkage between the BclI
marker and obesity (BMI  27), no
association after replication
Panarelli et al.,
1998
64 Men (aged 18–40 years) No association of the G-allele with BMI,
increased in vivo sensitivity to
budesonide in GG-carriers
Buemann et al.,
1997
79 Men and 73 women,
middle-aged
Increased abdominal visceral fat in lean GG
carriers but not in overweight GG
carriers
Rosmond et al.,
2000
262 Swedish men Increased abdominal obesity and higher
cortisol levels in GG carriers compared
to CC carriers
Ukkola et al.,
2001b
12 Pairs of monozygotic lean
male twins (aged 21
years)
CC carriers had a greater increase in weight,
abdominal visceral fat, and cholesterol
levels in response to overfeeding
compared to CG carriers
Ukkola et al.,
2001a
322 Men and 420 women
(aged 42 years)
G allele associated with abdominal visceral
fat and gene-gene interactions present
with lipoprotein lipase gene and
adrenergic receptor gene
Tremblay et al.,
2003
90 Male and 83 female
adolescents
Female CG carriers had a greater increase in
subcutaneous fat mass during a 12-year
follow-up than CC carriers or GG
carriers. No differences were found in
males
van Rossum et al.,
2003c
197 Dutch elderly subjects,
1963 elderly males and
females, 400 elderly
males
G allele associated with hypersensitivity to
both 1-mg and 0.25-mg dexamethasone
(in an allele-dosage way), lower BMI,
and a tendency towards lower lean
mass, while fat mass was not different
CC carriers, in previous reports, were described as homozygous 2.3 kb-allele carriers, CG
carriers as heterozygous 2.3/4.5 kb carriers, and GG carriers as homozygous 4.5 kb-allele carriers.
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more insulin resistant, when compared to a group consisting of CC (homozygous
2.3 kb) and CG (2.3/4.5 kb) carriers. In a report by Panarelli et al. (1998), no
association between the G allele and BMI was described. However, increased
skin vasoconstriction was observed in homozygous G-allele carriers after injec-
tion with budesonide, a synthetic GC, which suggests increased in vivo sensi-
tivity to GCs. In contrast, this study showed that the in vitro affinity and
sensitivity of leucocytes to DEX tended to be lower. Although these findings
were not statistically significant, they suggest that this polymorphism might have
tissue-specific effects. Three other reports, all in middle-aged individuals,
showed an association between the BclI polymorphism and abdominal visceral
obesity but not general obesity (Buemann et al., 1997; Rosmond et al., 2000b;
Ukkola et al., 2001a). GCs are known to induce central obesity, as observed in
Cushing’s disease. It is not known whether this polymorphism is associated with
other features of Cushing’s (e.g., easy bruising). However, the relationship
between abdominal obesity and the BclI polymorphism suggests a greater effect
of GCs due to alterations at the level of the GR, in particular, in visceral fat. This
was confirmed in an elderly Dutch population of 197 subjects with a mean age
of 67 years (van Rossum et al., 2003b). The carriers of the G allele of the BclI
polymorphism showed a greater suppression after 1-mg DEX as well as after
0.25-mg DEX (Figure 2D). This association was observed in an allele-dosage
way and suggests a hypersensitivity to GCs with respect to the negative-feedback
mechanism at the pituitary level. In a subset of 1963 subjects of the Rotterdam
study, effects of the BclI variant on body composition in the elderly were further
assessed (van Rossum et al., 2003b). The effects appeared to be the opposite of
those reported at a younger age: lower BMI in G-allele carriers. To further
explore whether this lower BMI was due to a smaller amount of fat mass or less
lean mass, we investigated an independent group of 370 Dutch males with a
mean age of 78 years (van Rossum et al., 2003b). Again, we observed a lower
BMI in G-allele carriers. We did not find differences in fat mass, although lean
mass tended to be lower in G-allele carriers in an allele-dosage way. Thus, the
slightly lower lean mass is in line with the previously observed hypersensitivity
to GCs in G-allele carriers. This suggests that, at an older age, lower BMI
possibly can be ascribed to muscle atrophy, which occurs in all healthy elder
individuals, but seems more pronounced in carriers of the G allele of the BclI
variant than in noncarriers.
In an 100-day experiment conducted with 12 pairs of monozygotic twins at
young-adult age, effects of the BclI variant were studied in relation to body
composition and metabolic changes in response to overfeeding (Ukkola et al.,
2001b). In this study, no homozygous G-allele carriers were found. In contrast
with these findings, CC carriers experienced a greater increase in body weight,
visceral fat, and cholesterol levels after overfeeding than CG carriers. However,
another study in adolescents showed that female heterozygous CG-allele carriers
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experienced a greater increase in subcutaneous fat, as measured by skinfold,
when compared to both homozygous CC carriers and GG carriers during a
12-year follow-up period (Tremblay et al., 2003). No differences were found in
baseline or post-follow-up subcutaneous fat mass, total fat mass, or, importantly,
trunk fat mass. The authors speculated that one mutated allele could have a
different effect than two mutated alleles. In the latter state, an alternative pathway
might be switched on to compensate for changes resulting from two polymorphic
alleles. Mechanisms supporting this theory have been reported in mouse models
involving cyclooxygenase-2 and glucose transporter-4 genes (Stenbit et al.,
1997; Fain et al., 2001). The results of Trembley et al. are not in line with the
allele-dosage associations between the BclI polymorphism and hypersensitivity
to GCs and BMI that we observed in our large elderly populations (van Rossum
et al., 2003b). However, at baseline, they show that female homozygous GG
carriers tend to have more subcutaneous fat than CC carriers and CG carriers.
Although this difference was not statistically significant, it might explain why
they did not find an even greater increase in GG carriers than in CG carriers
during follow-up. Thus, in this study, the GG carriers might already have been
slightly fatter at preadolescent age.
The molecular mechanism of the BclI polymorphism has not been
clarified. It is likely that this intronic polymorphism exerts its effects in a
different way than the N363S polymorphism. No alterations in glucose and
insulin metabolism have been observed in carriers of the BclI polymorphism
within the normal-weight population, while N363S carriers clearly showed an
increased insulin response to DEX. Only in obese carriers of the BclI
polymorphism were hyperinsulinemia and relative insulin resistance ob-
served. However, no transfection experiments are possible to elucidate the
mechanism, since the BclI polymorphism is located in an intron. We cannot
rule out the possibility that this intronic polymorphism is linked to another
polymorphism in the promoter region of the GR gene, which could result in
increased GR expression or a variant in the 3-untranslated region, which
could increase stability of mRNA. However, we did not observe any linkage
to the polymorphisms reviewed here (data not shown). Another possibility
could be linkage to another gene in the vicinity of the GR gene. Since in most
studies, the BclI polymorphism shows clear associations with increased
sensitivity to GCs, this possibility is less likely. It is also known that intronic
variations can influence the splicing process. However, the point mutation in
the BclI site is not located near a regulatory splice site.
In summary, contrasting data have been reported about the BclI polymor-
phism with respect to its association with body composition. A possible expla-
nation is that hypersensitivity to GCs due to the BclI polymorphism has different
consequences during life. It might be that early in life, fat mass — particularly
abdominal fat — is predominantly affected (i.e., BclI G-allele carriers have more
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fat), whereas later in life, the most-pronounced effects are observed on lean mass
(i.e., BclI G-allele carriers have lower lean mass).
IV. The ER22/23EK Polymorphism of the GR Gene
In a previous report, we described a polymorphism consisting of two linked,
single-nucleotide mutations in codons 22 and 23 (exon 2 of the GR gene) (Koper
et al., 1997). The first mutation in codon 22 did not result in an amino acid
change (GAG3 GAA, both coding for a glutamic acid (E)) but the mutation in
codon 23 (AGG3 AAG) caused a change from arginine (R) to lysine (K). In a
population of 202 randomly selected individuals from the Rotterdam study, a
population-based cohort study in the elderly, we found an association with higher
post-DEX cortisol levels (Figure 2E) as well as less cortisol suppression after a
1-mg DEX suppression test in ER22/23EK carriers (Figure 2F). This finding
suggests a relative GC resistance (van Rossum et al., 2002). In the same group
having a mean age of 67 years, we found that carriers of the ER22/23EK variant
had lower fasting insulin levels and increased insulin sensitivity (Figure 4).
Carriers of the ER22/23EK polymorphism also had lower total and low-density
lipoprotein cholesterol levels (Figure 5).
These findings of lower cholesterol and insulin levels were both confirmed
during a second measurement performed 2.5 years later. This suggests that
ER22/23EK carriers have a lower tendency to develop impaired glucose toler-
ance, type 2 diabetes, or cardiovascular disease. In line with these favourable
metabolic parameters, ER22/23EK polymorphism frequency was significantly
FIG. 4. (A) Fasting insulin concentrations in noncarriers and ER22/23EK carriers at first
examination. Insulin concentrations tended to be lower in ER22/23EK carriers compared to noncar-
riers (p  0.06). On the right, fasting insulin concentrations in noncarriers and ER22/23EK carriers
at second examination (2.5 years later). Fasting insulin concentrations were significantly lower in
ER22/23EK carriers (p  0.001). (B) Homeostasis model assessment-insulin resistance (HOMA-IR)
scores (index of insulin resistance) at baseline and at second examination 2.5 years later in noncarriers
and ER22/23EK carriers. At both measurements, ER22/23EK carriers were significantly less insulin
resistant.
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higher in the oldest half of the studied population. To further explore whether
there is an effect on survival at elder age of this polymorphism, we studied a
population of 402 men with a mean age of 77 years (van Rossum et al., 2004a).
After a follow-up of 4 years, 78 (19.2%) of the noncarriers died, while none of
the 21 heterozygous ER22/23EK carriers died, a statistically significant differ-
ence. It is has been shown that high C-reactive protein (CRP) is related to
increased risk of cardiovascular events (Liuzzo et al., 1994; Thompson et al.,
1995; Haverkate et al., 1997). In this population, it was shown that CRP and
interleukin-6 (IL-6) were strong predictors of survival (Feelders et al., 2003). We
found no differences in IL-6 levels between carriers and noncarriers of the
ER22/23EK variant; however, CRP levels were significantly lower in ER22/
23EK carriers (van Rossum et al., 2004a). This suggests that carriers of the
ER22/23EK variant are relatively protected from vascular damage. Furthermore,
total and LDL-cholesterol levels tended to be lower in ER22/23EK carriers,
although this did not reach statistical significance. All these data together suggest
that the better survival in ER22/23EK carriers might be due to a healthier
metabolic profile.
We also studied the effects of this polymorphism at a younger age by
investigating a cohort of 350 male and female subjects, who were followed from
the age of 13 until the age of 36 years. We studied whether anthropometric
parameters and body composition differed between ER22/23EK genotypes (van
Rossum et al., 2004b). In males aged 36 and 32 years, we found ER22/23EK
carriers to be, on average, 5 cm taller. Although there were no differences in BMI
or fat mass, lean body mass was significantly higher in male carriers of the
ER22/23EK variant. In accordance, their muscle strength, as measured by arm
pull tests and high jump from standing, also was significantly greater. These
FIG. 5. Total cholesterol (A) and low-density lipoprotein (LDL) cholesterol concentrations (B)
in noncarriers and ER22/23EK carriers at first examination. On the right side of each figure,
cholesterol concentrations in noncarriers and ER22/23EK carriers at second examination (2.5 years
later) are shown. At all measurements, ER22/23EK carriers had significantly lower total and
LDL-cholesterol levels than noncarriers.
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differences tended to be already present during puberty but reached statistical
significance only at young-adult age.
In females, different associations were observed with the ER22/23EK
variant. Waist circumferences tended to be smaller in female ER22/23EK carriers
at young-adult age but no differences in BMI were found. It is known that GCs
negatively affect muscle mass and induce abdominal obesity. Thus, at young-
adult age, the ER22/23EK variant is associated with beneficial changes in body
composition, which can possibly be explained by a relative resistance to GCs in
these tissues. In addition, effects of the ER22/23EK polymorphism seem to be
gender specific.
It is known that GCs influence important brain structures and a normal level
of cortisol is critical for many cerebral functions. In humans, high cortisol levels
have been found to result in decreased hippocampal formation volume and
memory impaiment (Starkman et al., 1992; Lupien et al., 1997). Disturbances in
the HPA axis have been found to be related to dementia disorders (Weiner and
Lourie, 1968; Gottfries et al., 1994; Nasman et al., 1995) In a large, population-
based study in the elderly, we studied whether the ER22/23EK polymorphism
was associated with hippocampal volume, dementia, and white matter lesions.
We found that ER22/23EK carriers had a lower risk of dementia as well as fewer
white matter lesions in the brain (van Rossum et al., 2003a). In addition, the
ER22/23EK polymorphism was associated with better performance on psy-
chomotor speed tests. It has been shown that white matter lesions are associated
with small vessel disease (Bots et al., 1993; Breteler et al., 1994). Thus, this
association might be a direct result of the beneficial effects of the ER22/23EK
polymorphism on metabolic risk factors for atherosclerosis. No associations were
found between the ER22/23EK variant and hippocampal volume. This might be
explained by the fact that, in basal conditions, most effects on the hippocampus
are mediated by the MR, while the GR plays a major role only in the activated
state (e.g., physical or psychological stress) (De Kloet and Reul, 1987). In other
parts of the brain, the GR is more important for mediating effects of GCs, so the
observed associations with dementia might be explained by a smaller direct
effect of GCs on the brain due to a relative GC resistance.
The mechanism that explains the effects of this polymorphism is under
study. Several possibilities exist through which this variation of the GR gene can
lead to these effects. Since the ER22/23EK polymorphism is located in the
transactivation domain, the arginine to lysine amino acid change might affect the
receptor’s tertiary structure, influencing the transactivational and/or transrepres-
sional activity on target genes (de Lange et al., 1997; Russcher et al., 2003).
Recently, it has been shown that two different methionine (M) codons in GR
mRNA may be used as the initiation codon: M1 and M27, resulting in two
isoforms, GR-A and GR-B, respectively. The GR-B protein has a stronger
transactivating effect in transient transfection experiments but no difference in
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transrepression (Yudt and Cidlowski, 2001). The nucleotide changes associated
with the ER22/23EK polymorphism might affect the secondary structure of the
GR mRNA, thus influencing the choice of initiation codon. Indeed, secondary
structure prediction (M-fold) showed different structures for the wild-type and
polymorphic mRNA. Another possible explanation for the decreased GC sensi-
tivity might be that the GR transactivational activity is affected by a different
GR-A/GR-B ratio (Russcher et al., 2003). A third option is that the ER22/23EK
variant might change mRNA stability, which is maintained when proteins
responsible for this stability bind to the mRNA molecule. If the polymorphic
mRNA recruits proteins in a different way, mRNA stability is affected, which
might be a clue for the decreased GC sensitivity in ER22/23EK carriers.
In summary, the ER22/23EK polymorphism of the GR gene is associated
with a relative GC resistance and a healthier metabolic condition, as evidenced
by lower cholesterol levels and increased insulin sensitivity. Furthermore, this
variant is associated with a beneficial body composition at young age and leads
to a lower risk of dementia and better survival in the elderly.
V. The TthIIII Polymorphism of the GR Gene
In the GR gene promoter region, a TthIIII RFLP previously was reported by
Detera-Wadleigh and colleagues (1991). Rosmond et al. (2000a) showed this
polymorphism to be associated with elevated diurnal cortisol levels in a popu-
lation of 284 Swedish men. No relationships were found between the TthIIII
variant and anthropometry, glucose, and insulin metabolism or lipid spectrum.
We recently identified the location of the nucleotide change: a C/T change, 3807
bp upstream of the GR mRNA start (Table II).
In the same subpopulation of the Rotterdam study in which we studied the
relationship between the three other polymorphisms described in this review and
feedback sensitivity to GCs, we investigated whether an association existed
between the TthIIII polymorphism and GC sensitivity (E.F.C. van Rossum, P.
Roks, F.H. de Jong, A.O. Brinkmann, H.A.P. Pols, J.W. Koper, S.W.J. Lamberts,
unpublished data). In this group, we found 39.7% CC carriers, 44.5% CT
carriers, and 15.8% TT carriers. No differences were found in cortisol levels
between the TthIIII genotypes before and after 1-mg and 0.25-mg DEX suppres-
sion, nor in anthropometric parameters, glucose and insulin levels, or cholesterol
concentrations. We also studied whether this TthIIII polymorphism interacted
with the N363S, BclI, and ER22/23EK polymorphisms. No interactions with
N363S or BclI were found. Interestingly, however, all carriers of the ER22/23EK
polymorphism carried the TthIIII T variant. This T allele of the TthIIII polymor-
phism is very common and exists without the ER22/23EK variant being present.
To study the effects of carrying the TthIIII T allele and the ER22/23EK
polymorphism, we compared the following three groups: 1) noncarriers of both
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polymorphisms (TthIIII CC and ER22/23ER); 2) carriers of one variant allele of
the TthIIII polymorphism (TthIIII CT/TT and ER22/23ER); and 3) carriers of
both polymorphisms (TthIIII CT/TT and ER22/23EK). The latter group had a
significantly reduced cortisol response to 1-mg DEX as well as lower insulin and
cholesterol levels, compared to the two other groups. No differences were found
between the group of noncarriers of both polymorphisms and the group of
carriers of only the TthIIII T variant. This suggests that the TthIIII polymorphism
is not functional by itself; it might be functionally relevant only in combination
with ER22/23EK. We do not know whether the TthIIII variant at the 5-flanking
region of the GR gene is essential in the associations of the ER22/23EK
polymorphism or if its presence at the same allele is coincidence and does not
influence the effects of the ER22/23EK variant. Possibly, the associations
Rosmond and coworkers (2000a) found between alterations in cortisol levels and
the TthIIII polymorphism could be explained by the presence of the ER22/23EK
variant. However, no data have been published on the ER22/23EK polymor-
phism in this Swedish population.
VI. Discussion
This review focused on several GR gene polymorphisms that were associ-
ated with body composition and metabolic parameters. As shown in Figure 1, the
three functional polymorphisms are located in exon 2 (transactivating domain)
and intron 2. This is in contrast to the previously described rare mutations
causing the syndrome of GC resistance, which are located predominantly in the
ligand-binding domain. GCs are essential for many regulatory processes in the
human body, so a mutation leading to an absolute resistance to GCs is not
compatible with life. The previously described patients, carrying a mutation of
the GR gene, have decreased negative feedback at the level of the pituitary gland,
which leads to HPA axis hyperactivation. Many of the symptoms found in
patients with GC resistance are the consequence of this compensatory increased
HPA axis activity: hyperandrogenism (in particular, leading to symptoms in
females and children before puberty) and increased mineralocorticoid effects.
The latter are due to exposure of the MR to high concentrations of cortisol, which
cannot be effectively inactivated by 11 HSD II.
Polymorphisms, common variations at the DNA level occurring in the
normal population with a frequency of more than 1%, have much more-subtle
effects. However, because of their high frequency in the population, their impact
may be much greater. In several — but not all — studies, polymorphisms in the
GR gene described here seem to correlate significantly with variation of sensi-
tivity to endogenous GCs in normal individuals. Table IV overviews the four
discussed polymorphisms and their relation with altered GC sensitivity. The
N363S and BclI polymorphisms both were associated with hypersensitivity to
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GCs, while the ER22/23EK polymorphism was associated with relative resis-
tance to GCs. No associations were found with the TthIIII polymorphism.
However, the ER22/23EK variant was found to be linked to the TthIIII poly-
morphism. In this respect, associations with GC resistance and beneficial meta-
bolic profile (i.e., low insulin and cholesterol levels) were observed in carriers of
both the ER22/23EK and TthIIII polymorphisms. Considering DEX suppression
test outcomes in carriers of the three functional polymorphisms, it seems that the
0.25-mg DEX suppression test is most sensitive to detect hypersensitivity to
GCs, while the 1-mg DEX suppression test may be more suitable to detect a
relative resistance to GCs.
Study of clinical associations of polymorphisms has several limitations. In
particular, when studies are performed in rather small populations, the risk that
the observed associations are based on coincidence will be increased. It is also
known that the general frequency of polymorphisms varies greatly between
ethnic populations. Thus, results from one population do not necessarily apply to
others. For example, the N363S polymorphism has been reported in Australia
with an allele frequency of 7.4% (Lin et al., 1999), whereas in two Asian studies
(Ikeda et al., 2001; Lei et al., 2003), no N363S carriers were found. Effects of
polymorphisms may differ between races, due to different combinations of
polymorphisms of several genes. Differences in environmental factors also play
an important role. In this respect, association studies performed in nonhomoge-
neous populations are difficult to interpret. Within similar ethnic populations,
observed associations with GR gene polymorphisms vary, which can be caused
by differences in characteristics of the study populations, environmental or
socioeconomic factors, or differences between generations. Furthermore, it is
known that in large population studies, unintended errors in data collection or
misclassifications occur relatively frequently, which can influence outcomes. A
limitation of GR gene polymorphism studies is that no in vitro mechanisms have
been clarified, while many associations have been found in vivo.
TABLE IV
Four Polymorphisms of the GR Gene, Studied in the Same Population in Relation to
Glucocorticoid Sensitivity
Polymorphism BclI N363S ER22/23EK TthIIII
N 191 216 202 205
Fasting cortisol ND ND ND ND
Sensitivity to 1-mg DEX Increased ND Decreased ND
Sensitivity to 0.25-mg DEX Increased Increased ND ND
[Abbreviations: N, number; DEX, dexamethasone; ND, no differences between genotype
groups of the above-mentioned polymorphism.]
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Observed associations with altered GC sensitivity may contribute to a better
understanding of the variations in regulation of the HPA axis between normal
individuals. Previous data suggest that the HPA axis setpoint in humans might be
genetically determined, since the intra-individual variations in post-DEX cortisol
concentrations are rather small (Huizenga et al., 1998b).
These GR gene polymorphisms may have modifying effects on conditions
such as (hereditary) atherosclerosis. It is known that some individuals survive
until a great age, although they have very high cholesterol levels (Weverling-
Rijnsburger et al., 1997). Thus, they might be protected by a genetic variant such
as the ER22/23EK. On the other hand, individuals who carry the N363S or the
BclI polymorphism might be more at risk for cardiovascular disease. The N363S
variant recently was found to be associated with coronary artery disease,
independent of obesity, as well as with increased total cholesterol and triglyc-
eride concentrations and an elevated total cholesterol/HDL ratio. Both the N363S
and the BclI polymorphism may predispose to obesity. However, as is well
known, environmental, dietary, and socioeconomic factors are also important
determinants of the obesity phenotype. Associations with polymorphisms depend
on many additional factors: differences in characteristics between populations,
prevalence of the polymorphism, and interactions with other genetic polymor-
phisms. These factors, taken together, might explain the discrepancies between
studies so far encountered.
In clinical practice, GCs are used widely to treat diseases (e.g., asthma,
chronic inflammations, prevention of rejection of organ transplants) as well as
replacement therapy. It is well known that effects of GC treatment vary consid-
erably between patients. Some patients respond very well to therapeutical
administration of GCs but also develop serious side effects, while others need a
very high dose to establish any clinical effect and do not suffer from side effects.
The response to GCs in the majority of patients lies between these extremes. It
is likely that these polymorphisms are to some extent responsible for the
variability in response to therapeutically used GCs. In the future, after appropri-
ate additional research, it might be useful to screen for the presence of these GR
gene variants, in order to determine an individual’s dose of GCs. This dose
should be adjusted to a person’s need, taking into account the genetically
determined GC sensitivity, in such a way that it is therapeutically effective but
does not cause side effects. We do not know whether the altered sensitivity
associated with these polymorphisms differs for various types of clinically used
GCs and whether the manner of application (e.g., local, systemic) influences the
effects of the polymorphisms.
During evolution, a selection process occurred in which some de novo
mutations probably had beneficial effects and slowly became more frequent in
the population. We found that the ER22/23EK variant in males was associated
with greater lean mass and muscle strength. In this view, the ER22/23EK
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polymorphism could have resulted in strong individuals with a greater chance to
survive due to an advantage in food-collecting and fighting ability. The N363S
and BclI carriers may have had advantages for survival through their tendency to
accumulate fat, which was especially favorable in times of food deficit. In this
respect, the BclI polymorphism probably arose long ago, since the allele fre-
quency in normal population is very high. However, in modern times of food
abundance, combined with increased psychological stress and lack of exercise,
the N363S and BclI polymorphisms may have turned into a disadvantage. An
increased sensitivity to GCs, resulting in fat accumulation, is probably a risk
factor in atherosclerosis. This is supported by the findings of increased risk of
coronary artery disease and obesity in N363S carriers in an Australian population
(Lin et al., 2003a,b).
In conclusion, the N363S, BclI, and ER22/23EK polymorphisms in the GR
gene, but not the TthIIII polymorphism, are associated with altered GC sensi-
tivity and result in a wide variety of phenotypic signs. These are not pathological
per se but may partially explain an individual’s genetically determined tendency
to a certain body composition and metabolic status (Figure 6). More research is
needed to elucidate the mechanisms behind these associations at a molecular
level.
FIG. 6. A tentative scheme of the N-terminal part of the glucocorticoid receptor gene in which
three functional polymorphisms are indicated as well as a summary of their clinical associations.
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